H.C. Wainwright Believes Protagonist Therapeutics (PTGX) Still Has Room to Grow

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics (PTGX) on October 30 and set a price target of $33.00. The company’s shares closed last Thursday at $23.05, close to its 52-week high of $23.25.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 13.0% and a 53.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Minerva Neurosciences, and Theravance Biopharma.

Protagonist Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $35.00.

See today’s analyst top recommended stocks >>

Based on Protagonist Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.22 million and GAAP net loss of $19.42 million. In comparison, last year the company had a GAAP net loss of $29.17 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts